Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Files to Begin Phase IIa Trial of HBV Drug

Premium

Arrowhead Research last month said that it has submitted a regulatory application seeking clearance to begin a phase IIa study of its RNAi-based hepatitis B treatment ARC-520.

ARC-520 comprises two distinct siRNAs targeting highly conserved genomic regions across the major HBV genotypes, and is formulated with a proprietary delivery technology called dynamic polyconjugates.

The planned phase IIa trial is slated to run in Hong Kong and test single, escalating doses of ARC-520 in combination with the antiviral entecavir in order to determine the "depth and duration of hepatitis B surface antigen reduction," according to Arrowhead.

In October, Arrowhead announced that preliminary phase I data showed the drug to be safe enough to advance into the next stage of human testing.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.